Latest news with #researchanddevelopment
Globe and Mail
2 days ago
- Business
- Globe and Mail
Blood Plasma Market to Witness Strong Growth at 10.8% CAGR, Expected to Hit USD 79.5 Mn by 2032
The trend in the blood plasma industry is characterized by a growing focus on research and development activities to develop novel plasma-derived therapies, increasing collaboration between plasma collection centers and pharmaceutical companies, and the expansion of plasma collection networks worldwide. Additionally, there is a growing emphasis on improving the safety and quality of plasma-derived products through stringent regulatory guidelines and advanced testing methodologies. Blood Plasma Market Insights The blood plasma industry has witnessed robust expansion driven by rising therapeutic demand and advanced manufacturing processes. Experts leverage novel fractionation techniques to meet growing immunoglobulin and albumin requirements, reflecting deep market research and market insights underpinning strategic decisions. The Global Blood Plasma Market size is estimated to be valued at USD 38.8 Mn in 2025 and is expected to reach USD 79.5 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.8% from 2025 to 2032. Market Key Takeaways - Region: - North America: robust regulatory framework and extensive donor networks enhance plasma availability. - Latin America: emerging collection centers in Brazil and Argentina drive capacity expansion. - Europe: strategic investments in fractionation plants support product diversification. - Asia Pacific: growing haemophilia treatment demand in China and India fuels capacity uptake. - Middle East: increasing collaborations improve regional self‐sufficiency in plasma derivatives. - Africa: pilot programs in South Africa strengthen plasma collection infrastructure. - Segment Covers: - Product Type: • Immunoglobulins: high‐volume IVIG therapies for autoimmune disorders. • Albumin: critical care applications in shock treatment. • Clotting Factors: haemophilia A and B management solutions. - Application: • Therapeutics: replacement therapies in immunodeficiency syndromes. • Diagnostics: plasma‐derived reagents for transfusion testing. - End‐User: • Hospitals: primary consumers of albumin and clotting factor concentrates. • Specialty Clinics: immunoglobulin administrations for chronic conditions. Growth Factors: Rising prevalence of immunodeficiency disorders and expanded market scope into recombinant fractions are key market drivers. Global immunoglobulin consumption reached 1,400 tons in 2024, up 8% year-on-year, offering significant market opportunities. Voluntary donor enrollment in North America surged 12% in 2024, driving a 7% uplift in collection volumes. Advanced fractionation capacity—such as the Octapharma Germany facility adding 50,000 L/month in mid-2024—bolstered supply. These drivers present market growth strategies alongside market challenges and restraints, supporting sustainable business growth and a projected 10.8% CAGR through 2032. Book the Latest Edition of this Market Study Get Up to 25 % Discount: Market Trends: Recent market research and market insights reveal accelerated AI-enabled donor screening that reduced deferral rates by 15% in 2024, enhancing supply reliability. Consolidation with regional partners—illustrated by Grifols' 2025 alliance in China—drives consolidation-driven market share shifts. Custom nano-scale chromatography methods achieved a 5% yield gain over conventional fractionation. Pressure from donor deferrals remains a key market restraint, while technological differentiation and regional capacity localization continue to define Blood Plasma Market trends and industry trends. Actionable Insights • Production Capacity: 5.2 M L/month global plasma processing in 2024, supporting an estimated market revenue uplift of USD 2.5 Mn monthly. • Pricing: IVIG average selling price at USD 90/g in Q4 2024, influencing overall market revenue stabilization. • Exports: U.S. plasma exports rose 9% in H2 2024 to 300k L, boosting supplier revenues. • Imports: EU plasma imports grew 11% in Q1 2025, reflecting demand-driven revenue influx. • Use Cases: APAC hospital albumin usage grew 7% in 2024, expanding revenue streams in critical care. • Micro-indicators: emerging nano-fractionation sites ( Key Players: • CSL Behring • Grifols • Takeda Pharmaceutical (formerly Shire) • Octapharma • Kedrion Biopharma • Bio Products Laboratory • LFB Group • Sanquin Plasma Products • China Biologic Products • ADMA Biologics • GC Pharma • CSL Plasma • Emergent BioSolutions • Kamada • Centurion Pharma Get Customization on this Report: Competitive Strategies: • CSL Behring's vertical integration of collection and fractionation in 2024 reduced COGS by 6% and improved margin by 2.3%. • Grifols' alliance with Shandong Weigao expanded plasma centers by 15 sites in China, increasing Asian Blood Plasma Market share. • Takeda's clinical partnerships with rare‐disease clinics in 2024 drove immunoglobulin adoption, boosting U.S. market revenue by 5%. • Kedrion Biopharma's targeted partnerships elevated its industry share among emerging biopharma companies by 3% in 2024. Frequently Asked Questions 1. Who are the dominant players in the Blood Plasma Market? Key players include CSL Behring, Grifols, Takeda, Octapharma, Kedrion Biopharma and others that account for major technological and capacity leadership. 2. What will be the size of the Blood Plasma Market in the coming years? The Blood Plasma Market size is projected to grow from USD 38.8 Mn in 2025 to USD 79.5 Mn by 2032 at a 10.8% CAGR. 3. Which end-user industry has the largest growth opportunity? Hospitals and specialty clinics administering IVIG and clotting factors for immunodeficiency and haemophilia represent the largest growth segments. 4. How will market development trends evolve over the next five years? Trends include AI-driven donor screening, nano-scale fractionation, and regional capacity localization as per the latest Blood Plasma Market report. 5. What is the nature of the competitive landscape and challenges in the Blood Plasma Market? The landscape remains consolidated, with key players pursuing vertical integration, regional alliances and facing donor-recruitment challenges as primary market restraints. 6. What go-to-market strategies are commonly adopted in the Blood Plasma Market? Strategies include strategic partnerships for capacity expansion, targeted clinical collaborations, differentiated fractionation technologies and localized regulatory approvals to drive market opportunities. About Coherent Market Insights Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Telegraph
11-06-2025
- Business
- Telegraph
Businesses ask just one thing from Rachel Reeves
The Chancellor is about to unveil her spending review. We know that business will welcome some of Rachel Reeves 's decisions – £113bn of capital investment and £86bn of research and development spending are not to be sniffed at. The British Chambers of Commerce represents 50,000 companies and I have already congratulated the Government on these investments. These are real, tangible steps that will help to drive growth throughout the economy. Importantly, those investments represent spades in the ground and projects that will benefit not just their local areas, but the entire country. The Government committing £14.2bn to the Sizewell C nuclear power station is a perfect example, and will help to create thousands of new jobs. But our members are clear, there is more to be done if the Government is to deliver an improvement in growth. Whether it's ever-increasing costs, a difficult labour market or crippling barriers to trade, British companies face serious challenges. Our latest research shows that less than half of businesses predict their turnover will grow this year. Just think about that. It means most businesses, when asked, believe that at best they will stand still. And standing still, with inflation pushing up costs, in reality means falling further and further behind. The cost of doing business has never been higher. From energy prices to National Insurance, companies are being hamstrung by factors outside their control. Previously profitable companies are stuck treading water and two in every three businesses say that tax is their biggest concern. On top of that, the Government is pushing ahead with its employment reforms. By its own measure, this will be another £5bn cost to business – and that's just the early estimate. Make no mistake, this continual piling up of costs cannot continue. And while the spending review is important, it's the Budget that fills business with dread. Another round of revenue-raising off the backs of Britain's entrepreneurs could put thousands of firms under. For many, there is nothing more to give. That's why we have one simple ask of the Government: no new taxes on business. Businesses can't afford it. The country can't afford it. Any additional pressure would damage what the Government says is its main priority: growth. Private enterprise is the real engine at the heart of our economy. It's our responsibility to make sure it has what it needs to succeed. Every week, I see first-hand the huge impact cost pressures are having on companies, particularly the National Insurance increase. From a manufacturer in the East Midlands being forced to make redundancies, to a logistics company in Aberdeen having to scale back its investment in projects. Companies are being buried under an avalanche of costs and we need the Government to publish a roadmap for how it will reduce the tax burden on businesses over time. No new taxes has to be the starting point. But to drive growth in the years ahead, the Government needs to lower cost pressures on companies. Despite the challenges, the pain and the pressures business owners face, what strikes me when I speak to founders and chief executives is how optimistic they remain. They still believe in themselves, and they still believe in Brand Britain. They don't want handouts from the Government but they do need ministers to look again at how they can relieve some of the cost pressures over which they have influence. If the Government gets that right, the rewards will be immense. Businesses just need to be given more opportunity. If they are given a chance, then they will seize it.
Geek Wire
22-05-2025
- Business
- Geek Wire
Tech Alliance study: R&D imbalance threatens state's innovation sector as public investment lags
Washington patent filings fell 23.4% from 2018 to 2023 — nearly five times the national average decline — despite the state's strong investment in research and development. Source: USPTO / Technology Alliance Benchmarking Report Washington ranks among the nation's top three states in business R&D spending, but weaker public investment is threatening the innovation ecosystem — a gap reflected in declining patent activity and limited startup diversity. That is one of the key takeaways in the 2025 Benchmarking Report from the Technology Alliance, which says Washington is relying too heavily on private companies to drive innovation, while public investment and basic research fall behind. Washington leads most states in private-sector research spending, with business R&D accounting for 98.6% of total R&D investment. That strength is not matched by academic and federal contributions, which make up less than 1.5% combined. Patent filings in Washington state have dropped 23% in five years, and the number of patents issued has fallen nearly 59%, raising concerns about the long-term output of the state's innovation pipeline. The report also notes that Washington's startup activity remains heavily concentrated in IT and healthcare, with fewer ventures emerging from basic science, clean energy, advanced materials, or other research-driven sectors. Washington's R&D spending climbed sharply after 2017 to reach 8% of state GDP by 2021. Source: Science & Engineering State Indicators / Technology Alliance Benchmarking Report That narrow focus, the report warns, could make the state less resilient to future economic cycles without greater investment in foundational research and public-sector support. Washington is in the top three states with R&D spending equal to 8% of the state's gross domestic product, said Chelsea Tucker, managing director at Accenture, presenting the findings at this week's Technology Alliance State of Technology Luncheon in downtown Seattle. 'We should be really proud of where we rank in R&D,' she said. 'When I read that, I really had to make sure my eyes weren't going cross. I think that's staggering.' However, as an indicator, she called the trends in patent filings a cause for concern. 'What do we need to do to guarantee that the organizations investing in R&D are motivated to continue?' Tucker said. 'I think we need to be introspective … to make sure that those R&D investments don't go down.' Chelsea Tucker, managing director at Accenture, presents findings from the 2025 Innovation Benchmarking Report at the Technology Alliance State of Technology Luncheon in Seattle. (Photo by Melissa Ponder for the Technology Alliance) The report calls for greater public investment in academic and federal research to help balance Washington's heavy reliance on private-sector R&D, while expanding support for basic research. The report also urges state leaders to maintain a competitive business environment to keep corporate R&D dollars in Washington and support continued economic growth. The report provided a backdrop for business and policy leaders — including Microsoft President Brad Smith — to call for renewed public investment and stronger innovation policy during the event. But the recommendations face a harsh reality of federal spending cuts and a shaky state economy. Washington is grappling with a $16 billion budget shortfall, leading to new business taxes and prompting the state to scale back key economic development programs. This year's version of the Benchmarking Report was authored by Ananya Yashasvi, the William H. Gates Sr. Fellow in Innovation and Entrepreneurship at the Technology Alliance, with guidance from Martin Stoddart, a managing director at Accenture. Accenture, the University of Washington, and Microsoft also contributed data and expertise to the report. See this year's report and past versions here.
Yahoo
16-05-2025
- Business
- Yahoo
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ...
Cash and Cash Equivalents: $102.3 million at the end of Q1 2025. Net Cash Used in Operating Activities: $29.3 million for Q1 2025. Collaboration Revenue: $2.8 million for Q1 2025, down from $9.2 million in Q1 2024. Research and Development Expenses: $18.3 million for Q1 2025, compared to $18.7 million in Q1 2024. General and Administrative Expenses: $8.9 million for Q1 2025, down from $11.6 million in Q1 2024. Net Loss: $24.1 million for Q1 2025, compared to $19.3 million in Q1 2024. Warning! GuruFocus has detected 5 Warning Signs with MRSN. Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Mersana Therapeutics Inc (NASDAQ:MRSN) has implemented a strategic restructuring plan to extend its cash runway into mid-2026, allowing for continued development of its key product, Emi-Le. The company reported promising clinical data for Emi-Le, particularly in patients with B7-H4 high tumors, showing an objective response rate (ORR) of 29% and a median progression-free survival (PFS) of 16 weeks. Enrollment in the expansion cohort for Emi-Le has progressed rapidly, indicating strong interest and potential for further clinical success. Mersana Therapeutics Inc (NASDAQ:MRSN) has adopted new proteinuria management guidelines, which are expected to improve treatment tolerability and maintain dose intensity. The company has a solid financial position with $102.3 million in cash and cash equivalents, supporting its operations into mid-2026 without relying on future milestone payments or collaborations. Mersana Therapeutics Inc (NASDAQ:MRSN) has reduced its workforce by about 55% and eliminated internal pipeline development efforts, which may impact future innovation and development capabilities. The company's collaboration revenue decreased significantly from $9.2 million in Q1 2024 to $2.8 million in Q1 2025, reflecting reduced revenue from partnerships with J&J and Merck KGaA. Despite restructuring efforts, Mersana reported a net loss of $24.1 million for Q1 2025, an increase from the $19.3 million net loss in the same period of 2024. The focus on breast cancer in clinical development may limit the exploration of Emi-Le's potential in other tumor types, as expansion efforts in ovarian and endometrial cancers have been deprioritized. The company faces challenges in managing proteinuria, a side effect of Emi-Le, which requires careful mitigation strategies to avoid treatment delays and maintain efficacy. Q: Can you expand on the high dose, especially regarding safety and the updated protocol? Will this be included in the ASCO update? A: Brian Deschuytner, CFO and COO, explained that the data shared at ASCO will be based on escalation and backfill only, not expansion. The 44.5 mg/m dose is distinct and higher than the 67.4 mg/m dose, ensuring meaningful exposure. The 44.5 mg/m dose showed effectiveness in tumor reduction, but proteinuria management is crucial to maintain treatment without interruptions. Q: How might the ASCENT 3 and ASCENT 4 studies impact your clinical development plans in the post topo setting? A: Brian Deschuytner noted that the earlier use of topo-1 ADCs could expand the post topo-1 patient pool, where Mersana's Emi-Le has shown activity. This development is positive for patients and the opportunity size Mersana is pursuing. Q: Could you comment on the types of patients who showed responses at the intermediate dose? Also, how effective have the proteinuria management strategies been? A: Martin Huber, CEO, stated that the two additional responses were in ACC 1 patients. The proteinuria management strategies are not expected to eliminate proteinuria but aim to manage its consequences. The company is confident in these efforts and will share more details in the second half of the year. Q: Are there additional dosing regimens being evaluated beyond the current ones in expansion? What can we expect from the upcoming ASCO presentation? A: Brian Deschuytner confirmed that the current two doses are the focus for expansion, with no plans for additional regimens. The ASCO presentation will focus on backfill and escalation data, not expansion data. Q: Could you provide more color on a potential pivotal study and the cutoff for B7-H4 expression? A: Martin Huber discussed the benefits of a randomized trial over a single-arm trial, including global filing opportunities and avoiding confirmatory trials. The B7-H4 expression cutoff is being refined in expansion, but 40-50% of patients are expected to be positive. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
09-05-2025
- Business
- Bloomberg
Tech Industry Warns US Investment Pledges Hinge on Research Tax Break
Major tech companies lobbying to salvage a tax deduction for research and development are warning they may pull back from high-profile pledges of new US investments if Congress doesn't fully reinstate the break. Big tech companies have pledged more than $1.6 trillion in investments in the US since Donald Trump took office, promising to build factories and data centers in alignment with Trump's push to build in America.
